A BILL FOR AN ACT

RELATING TO THE UNIFORM CONTROLLED SUBSTANCES ACT.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

1 SECTION 1. Section 329-22, Hawaii Revised Statutes, is 2 amended to read as follows: 3 **"§329~22 Schedule V.** (a) The controlled substances listed in this section are included in schedule V. 4 5 Narcotic drugs containing nonnarcotic active medicinal 6 ingredients. Any compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs, which 7 also contains one or more nonnarcotic active medicinal ingredients 8 9 in sufficient proportion to confer upon the compound, mixture, or 10 preparation, valuable medicinal qualities other than those 11 possessed by the narcotic drug alone: 12 Not more than 200 milligrams of codeine, or any of its (1)13 salts, per 100 milliliters or per 100 grams; 14 (2) Not more than 100 milligrams of dihydrocodeine, or any 15 of its salts, per 100 milliliters or per 100 grams;

Not more than 100 milligrams of ethylmorphine, or any of

its salts, per 100 milliliters or per 100 grams;

2019-2929 HB290 SD2 SMA-1.doc

(3)

16

17

1	(4)	Not more than 2.5 milligrams of diphenoxylate and not
2		less than 25 micrograms of atropine sulfate per dosage
3		unit;
4	(5)	Not more than 100 milligrams of opium per 100
5		milliliters or per 100 grams; and
6	(6)	Not more than 0.5 milligram of difenoxin and not less
7		than 25 micrograms of atropine sulfate per dosage unit.
8	(c)	Stimulants. Unless specifically exempted or excluded
9	or unless	listed in another schedule, any material, compound,
10	mixture,	or preparation that contains any quantity of the
11	following	substances having a stimulant effect on the central
12	nervous s	ystem, including its salts, isomers, and salts of
13	isomers.	
14	(d)	Depressants. Unless specifically exempted or excluded
15	or unless	listed in another schedule, any material, compound,
16	mixture,	or preparation that contains any quantity of the
17	following	substances having a depressant effect on the central
18	nervous s	ystem, including its salts, isomers, and salts of
19	isomers:	
20	(1)	Lacosamide [(R)-2-acetoamido-N-benzyl-3-methoxy-
21		propionamide], (Vimpat);

1	(2)	Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic			
2		acid]; and			
3	(3)	Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-			
4	÷	yl]butanamide) (Other names: BRV; UCB-34714; Briviact)			
5		and its salts.			
6	<u>(e)</u>	Approved cannabidiol drugs. A drug product in			
7	finished	dosage formulation that has been approved by the United			
8	States Fo	od and Drug Administration that contains cannabidiol			
9	(2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-				
10	pentyl-1,3-benzenediol) derived from cannabis and no more than				
11	0.1 per c	ent (w/w) residual tetrahydrocannabinols."			
12	SECT	ION 2. Section 329-38, Hawaii Revised Statutes, is			
13	amended b	y amending subsection (i) to read as follows:			
14	"(i)	Prescriptions for controlled substances shall be			
15	issued on	ly as follows:			
16	(1)	All prescriptions for controlled substances shall			
17		originate from within the State and be dated as of,			
18		and signed on, the day when the prescriptions were			
19		issued and shall contain:			
20		(A) The first and last name and address of the			
21		patient; and			

1		(B) The drug name, strength, dosage form, quantity
2		prescribed, and directions for use. Where a
3		prescription is for gamma hydroxybutyric acid,
4		methadone, or buprenorphine, the practitioner
5		shall record as part of the directions for use,
6		the medical need of the patient for the
7		prescription.
8	I	Except for electronic prescriptions, controlled
9	Ş	substance prescriptions shall be no larger than eight
10	á	and one-half inches by eleven inches and no smaller
11	t	than three inches by four inches. A practitioner may
12) · · · · · · · · · · · · · · · · · · ·	sign a prescription in the same manner as the
13	I	practitioner would sign a check or legal document
14		(e.g., J.H. Smith or John H. Smith) and shall use both
15	7	words and figures (e.g., alphabetically and
16	I	numerically as indications of quantity, such as five
17		(5)), to indicate the amount of controlled substance
18	1	to be dispensed. Where an electronic prescription is
19	1	permitted, either words or figures (e.g.,

alphabetically or numerically as indications of

quantity, such as five or (5)), to indicate the amount

20

21

1	of controlled substances to be dispensed shall be
2	acceptable. Where an oral order or electronic
3	prescription is not permitted, prescriptions shall be
4	written with ink or indelible pencil or typed, shall
5	be manually signed by the practitioner, and shall
6	include the name, address, telephone number, and
7	registration number of the practitioner. The
8	prescriptions may be prepared by a secretary or agent
9	for the signature of the practitioner, but the
10	prescribing practitioner shall be responsible in case
11	the prescription does not conform in all essential
12	respects to this chapter and any rules adopted
13	pursuant to this chapter. In receiving an oral
14	prescription from a practitioner, a pharmacist shall
15	promptly reduce the oral prescription to writing,
16	which shall include the following information: the
17	drug name, strength, dosage form, quantity prescribed
18	in figures only, and directions for use; the date the
19	oral prescription was received; the full name, Drug
20	Enforcement Administration registration number, and
21	oral code number of the practitioner; and the name and

H.B. NO. 290 H.D. 1

address of the person for whom the controlled		
substance was prescribed or the name of the owner of		
the animal for which the controlled substance was		
prescribed.		

A corresponding liability shall rest upon a pharmacist who fills a prescription not prepared in the form prescribed by this section. A pharmacist may add a patient's missing address or change a patient's address on all controlled substance prescriptions after verifying the patient's identification and noting the identification number on the back of the prescription document on file. The pharmacist shall not make changes to the patient's name, the controlled substance being prescribed, the quantity of the prescription, the practitioner's Drug Enforcement Administration number, the practitioner's name, the practitioner's electronic signature, or the practitioner's signature;

(2) An intern, resident, or foreign-trained physician, or a physician on the staff of a Department of Veterans

Affairs facility or other facility serving veterans,

1	exempted from registration under this chapter, shall
2	include on all prescriptions issued by the physician:
3	(A) The registration number of the hospital or other
4	institution; and
5	(B) The special internal code number assigned to the
6	physician by the hospital or other institution in
7	lieu of the registration number of the
8	practitioner required by this section.
9	The hospital or other institution shall forward a copy
10	of this special internal code number list to the
11	department as often as necessary to update the
12	department with any additions or deletions. Failure
13	to comply with this paragraph shall result in the
14	suspension of that facility's privilege to fill
15	controlled substance prescriptions at pharmacies
16	outside of the hospital or other institution. Each
17	written prescription shall have the name of the
18	physician stamped, typed, or hand-printed on it, as
19	well as the signature of the physician;
20 (3)	An official exempted from registration shall include
21	on all prescriptions issued by the official:

1		(A)	The official's branch of service or agency (e.g.,
2			"U.S. Army" or "Public Health Service"); and
3		(B)	The official's service identification number, in
4			lieu of the registration number of the
5			practitioner required by this section. The
6			service identification number for a Public Health
7			Service employee shall be the employee's social
8			security or other government issued
9			identification number.
10		Each	prescription shall have the name of the officer
11		stam	ped, typed, or handprinted on it, as well as the
12		sign	ature of the officer; and
13	(4)	A ph	ysician assistant registered to prescribe
14		cont	rolled substances under the authorization of a
15		supe	rvising physician shall include on all controlled
16		subs	tance prescriptions issued:
17		(A)	The Drug Enforcement Administration registration
18			number of the supervising physician; and
19		(B)	The Drug Enforcement Administration registration
20			number of the physician assistant.

1		Each written controlled substance prescription issued				
2		shall include the printed, stamped, typed, or hand-				
3		printed name, address, and phone number of both the				
4		supervising physician and physician assistant, and				
5		shall be signed by the physician assistant. The				
6		medical record of each written controlled substance				
7		prescription issued by a physician assistant shall be				
8		reviewed and initialed by the physician assistant's				
9		supervising physician within seven working days."				
10	SECTION 3. Section 329-122, Hawaii Revised Statutes, is					
11	amended b	y amending subsection (f) to read as follows:				
12	"(f)	For the purposes of this section, "transport" means				
13	the trans	portation of cannabis, usable cannabis, or any				
14	manufactu	red cannabis product between:				
15	(1)	A qualifying patient and the qualifying patient's				
16		primary caregiver;				
17	(2)	A qualifying out-of-state patient under eighteen years				
18		of age and the caregiver of a qualifying out-of-state				
19		patient;				
20	(3)	The production centers and the retail dispensing				
21		locations under a dispensary licensee's license; or				

1	(=)	A prod	action contor, recall albeining rocation,
2		qualif	ying patient, primary caregiver, qualifying out-
3		of-sta	te patient, or caregiver of a qualifying out-of-
4		state	patient and a certified laboratory for the
5		purpos	e of laboratory testing; provided that a
6		qualif	ying patient, primary caregiver, qualifying out-
7		of-sta	te patient, or caregiver of a qualifying out-of-
8	,	state	patient may only transport up to one gram of
9		cannab	is per test to a certified laboratory for
10		labora	tory testing and may only transport the product
11		if the	qualifying patient, primary caregiver,
12		qualif	ying out-of-state patient, or caregiver of a
13		qualif	ying out-of-state patient:
14		(A) S	ecures an appointment for testing at a certified
15		1	aboratory;
16		(B) C	btains confirmation, which may be electronic,
17		t	hat includes the specific time and date of the
18		а	ppointment and a detailed description of the
19		p	roduct and amount to be transported to the
20		C	ertified laboratory for the appointment; and

1	(C) Has the confirmation, which may be electronic,
2	available during transport.
3	For purposes of interisland transportation, "transport" of
4	cannabis, usable cannabis, or any manufactured cannabis product,
5	by any means is allowable only by a qualifying patient or
6	qualifying out-of-state patient for the patient's personal
7	medical use, or between a production center or retail dispensing
8	location and a certified laboratory for the sole purpose of
9	laboratory testing pursuant to section 329D-8, as permitted
10	under section 329D-6(m) and subject to section 329D-6(j), and
11	with the understanding that state law and its protections do not
12	apply outside of the jurisdictional limits of the State.
13	[Allowable transport pursuant to this section does not include
14	interisland transportation by any means or for any purpose
15	between a qualified patient, primary caregiver, qualifying out-
16	of-state patient, or caregiver of a qualifying out-of-state
17	patient and any other entity or individual, including an
18	individual who is a qualified patient, primary caregiver,
19	qualifying out of state patient, or caregiver of a qualifying
20	out of state patient.] The department of transportation and

- 1 department of public safety shall adopt rules pursuant to
- 2 chapter 91 necessary for the purposes of this subsection."
- 3 SECTION 4. Statutory material to be repealed is bracketed
- 4 and stricken. New statutory material is underscored.
- 5 SECTION 5. This Act shall take effect upon its approval.

H.B. NO. ²⁹⁰
_{S.D. 2}

Report Title:

Uniform Controlled Substances Act; Medical Cannabis; Interisland Transportation

Description:

Updates the Uniform Controlled Substances Act to make it consistent with amendments in federal controlled substances law as required under the authority to schedule controlled substances. Authorizes qualifying patients or qualifying outof-state patients to transport medical cannabis between islands for their personal medical use. (SD2)

The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.